Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
October 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” DA-9401 can protect against finasteride-induced reproductive damage in rats.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
4 citations
,
April 2009 in “Journal of Pain” Finasteride boosts morphine's pain relief and prevents tolerance and withdrawal in rats.
25 citations
,
October 2008 in “Chromatographia” A fast and accurate method was developed to measure alfuzosin and dutasteride in human plasma.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
March 2022 in “Nepal Journal of Dermatology Venereology & Leprology” Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.
69 citations
,
October 2013 in “Journal of Clinical Psychopharmacology” Naltrexone did not significantly reduce hair pulling but improved cognitive flexibility.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
24 citations
,
January 1996 in “The Prostate” Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
April 2020 in “Journal of the Endocrine Society” Block and replace therapy improved symptoms in recurrent cyclic Cushing’s disease.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
20 citations
,
January 2000 in “Dermatologic Clinics” New psoriasis treatments are effective but come with side effects and risks.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
January 2018 in “Repositorio de Tesis - UNMSM” Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
3 citations
,
January 2023 in “Clinical cancer investigation journal” Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.
September 2024 in “Dermatology” Dutasteride works better than finasteride for hair loss and has mild, reversible side effects.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
April 2026 in “Brain Sciences” Finasteride may cause depression and suicidal thoughts, especially in young men.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.